Many recent studies have demonstrated that FN is upregulated in cancer tissues, with reappearance of alternatively spliced isoforms. [6] [7] [8] [9] In breast cancers, immunohistochemical studies using specific monoclonal antibodies have demonstrated that FN isoforms, including EDA (EDA + FN) and EDB (EDB + FN) can be detected in cancer stroma. [10] [11] [12] In contrast, it has been considered that the effect of the splicing may be quantitative rather than qualitative, 13) and the functional significance of molecular differences has yet to be clarified in detail. However, recent studies have demonstrated that EDA + FN exhibits a high affinity for integrin, 14) and EDB + isoform induces tyrosine phosphorylation of focal adhesion proteins.
The expression of fibronectin (FN) isoforms including extra domain A (EDA) and extra domain B (EDB) segments, was investigated in 36 invasive
Key words: Fibronectin -EDA -EDB -Breast cancer Fibronectin (FN) is an adhesive extracellular matrix glycoprotein, which is involved in many kinds of cellular events including proliferation, migration and differentiation. The cellular FN molecule has three segments, which can be alternatively spliced at the mRNA level: EDA (extra domain A), EDB (extra domain B) and IIICS (type III homology connecting segment) regions. The splicing patterns of these segments are developmentally regulated and are tissue-or cell-type specific, [1] [2] [3] [4] [5] expression being very limited in normal adult tissues.
Many recent studies have demonstrated that FN is upregulated in cancer tissues, with reappearance of alternatively spliced isoforms. [6] [7] [8] [9] In breast cancers, immunohistochemical studies using specific monoclonal antibodies have demonstrated that FN isoforms, including EDA (EDA + FN) and EDB (EDB + FN) can be detected in cancer stroma. [10] [11] [12] In contrast, it has been considered that the effect of the splicing may be quantitative rather than qualitative, 13) and the functional significance of molecular differences has yet to be clarified in detail. However, recent studies have demonstrated that EDA + FN exhibits a high affinity for integrin, 14) and EDB + isoform induces tyrosine phosphorylation of focal adhesion proteins. 15) To establish the possible roles of different FN isoforms in cancer progression, it is important to clarify the cellular sources of these isoforms. Therefore, we examined mRNA expression of EDA and EDB, and well as total FN isoforms, by in situ hybridization (ISH) using cRNA probes specific to the constant region and alternatively spliced sites, in benign and malignant human breast lesions.
MATERIALS AND METHODS
Tissues A total of 49 human breast tumors (36 invasive ductal carcinomas and 13 benign tumors) were investigated. All tissues were surgically resected, and immediately fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (PB), pH 7.4, at 4°C overnight. After having been rinsed in PB, they were dehydrated through a graded ethanol series and xylene, embedded in paraffin, sectioned at 4 µm, and placed on silane-coated glass slides (Dako Japan, Kyoto).
Histological classification was made using sections stained with hematoxylin and eosin. To examine the relationship of expression of FN isoforms to morphological features, we classified the lesions according to the histological patterns of their cancer nests (large or small) and stroma (desmoplastic or not desmoplastic). Cases in the 'large cancer nests' group had more than 50% of their cancer nests, including intraductal lesions, over 200 µm in diameter. The 'desmoplastic' cases had more than 50% desmoplastic stroma. Preparation of digoxigenin (DIG)-labeled cRNA probes and ISH Human FN cDNAs were generous gifts from Dr. K. Sekiguchi (Osaka). cDNA inserts were subcloned in pGEM-3Z or pGEM-4Z (Promega Corporation, Madison, WI). The inserts for the constant region were: (1) 8th type I repeat-4th type III repeat, a 1069 bp SalI-PstI insert, (2) 6th-9th type III repeats without EDB, a 919 bp PstIBamHI insert. Inserts of 270 bp and 273 bp were used for the EDA and EDB segments, respectively. DIG-labeled cRNAs and ISH were prepared using the previously described methods. 16, 17) cRNA probes for tenascin-C (TN-C) were generated as described elsewhere. 17, 18) Hybridization signals were detected using alkaline-phosphatase-conjugated anti-DIG antibodies and visualized by incubation in nitrotetrazolium blue/5-bromo-4-chloro-3-indolyl phosphate solution. The sections were then counterstained with 0.1% nuclear fast red in 5% aluminum sulfate solution.
Tumors showing multifocal to diffuse distributions having more than 10 positive cells per ×40 objective field were evaluated as positive. Quantification of proportions of FN mRNA-positive cells labeled with EDA and EDB segments To examine the proportions of EDA-and EDB-labeled cells, 9 cases showing strong labeling of cancer cells by FN mRNA were chosen from the 'large cancer nest' group for detailed analysis. In ten high-power fields for each case, FN mRNA-positive cancer cells were counted, and then the cells labeled with EDA and EDB probes were counted in the same fields in serial sections. For analysis of expression by stromal cells, 13 cases were chosen from the 'desmoplastic' group. The data are presented as total numbers of EDA + or EDB + mRNA-positive cells/total numbers of FN mRNA-positive cells×100 (%). Expression of FN mRNAs by cancer cells was most frequent in intraductal lesions and large cancer nests with papillary projections and tubular formations. Positive cells were often found at the margins of a cancer nest in contact with mesenchymal elements (Fig. 1A) . Some of these cells could be shown to be positive for EDA and/or EDB (Fig. 1, B and C) . Expression of the EDA + mRNA by stromal cells was often associated with an active desmoplastic reaction (Fig. 1E) . In peripheral areas of the cancer tissues, EDA + mRNA was frequently observed. In hyalinized stroma in the tumor center, EDA + and EDB + mRNA signals were completely lacking, but some cells were labeled by the constant region probe detecting all FN isoforms.
RESULTS

Breast cancers
Cancers were classified according to the size of the cancer nests and extent of the desmoplastic reaction. In large cancer nests, mRNA signals for FN were found in 68% and for EDA + and EDB + in 64% and 45%. The figures for intraductal lesion were especially high at 100%, 91% and 58%, respectively. Small cancer nests were less likely to include positive cells (Table I) . Expression of EDA + FN mRNA was found in 94% and 47%, respectively, of cases with or without a desmoplastic reaction.
Expression of EDB
+ mRNA by the stromal cells was rare (Fig. 1F) .
In addition, we examined the proportions of the cells expressing EDA and EDB segments with respect to the cells labeled with the constant region probe for FN isoform. In representative cases with large cancer nests, EDA + and EDB + mRNAs were expressed in 45% and 39% of the FN mRNA-positive cancer cells, respectively, both being (EDA + /EDB + FN) frequently labeled in the same cells. In stromal cells of desmoplastic areas, the EDA + and EDB + mRNAs were labeled in 25% and 6% of the FN mRNA-positive stromal cells, respectively. Benign lesions Expression of FN isoforms in benign lesions of the human breast was studied using 8 fibroadenomas, 3 cases of fibrocystic disease and 2 intraductal papillomas (Table II) . In the fibroadenomas, FN mRNA 
interstitial tissues surrounding the duct. EDB + FN proved negative in all the benign lesions. Co-expression of EDA + + + + FN and TN-C We have previously reported that TN-C and FN are co-expressed by cancer and stromal cells. 17) Cancer cells at the margin of intraductal lesions and stromal cells in desmoplastic lesions were here also found to co-express EDA + FN and TN-C mRNA (Fig. 2) . A recent biochemical study demonstrated that insertion of the EDA segment into FN molecules enhances the integrin-binding affinity, promoting cell adhesion. In addition, cell migration is stimulated. 14) In the light of these biochemical properties and expression patterns of FN containing EDA, it could be considered that FN isoforms stimulate migration activity of cancer cells, associated with intraductal extension of cancer cells and invasion from the ducts or nests. Motility of the stromal cells may also be enhanced by EDA + FN deposited in cancer stroma, followed by remodeling of the stroma. In addition, this isoform could promote cancer cell invasion in the stroma. We recently reported a high rate of expression of TN-C mRNA in breast cancer, and as confirmed here, this may be linked to expression of EDA + FN. Since TN-C also enhances migration, 20, 21) these proteins may act synergistically. Another biochemical study reported that, leading to tyrosine phosphorylation of focal adhesion proteins, EDB domain induces cell signaling events by a mechanism different from that mediated by integrins through RGD and the synergistic sequences of FN type III8-9-10.
DISCUSSION
15) The expression of the EDB + isoform in vivo is more restricted than that of the EDA + isoform. 2, 10) This ISH study demonstrated that cancer cells are a major cellular source of FN containing EDB. The EDB + isoform possibly acts on cancer cells in an autocrine manner. Thus, the preferential production of this isoform by cancer cells, but not in benign tumors, and the EDB-dependent signaling could have special significance in tumor malignancy.
In conclusion, the splicing pattern of FN pre-mRNA is cell type-specific, and histology-dependent in breast cancer tissues. FN isoforms containing EDA and/or EDB and their production by cancer and stromal cells might play important roles in cancer progression.
